Publications by authors named "Tiffany Gervasi-Follmar"
The study examined changes in the plasma proteome, metabolome, and lipidome of N = 14 patients with relapsing-remitting multiple sclerosis (RRMS) initiating treatment with ocrelizumab, assayed at baseline, 6 months, and 12 months. Analyses of >4000 circulating biomarkers identified depletion of B-cell associated proteins as the early effect observed following ocrelizumab (OCR) initiation, accompanied by the reduction in plasma abundance of cytokines and cytotoxic proteins, markers of neuronaxonal damage, and biologically active lipids including ceramides and lysophospholipids, at 6 months. B-cell depletion was accompanied by decreases in B-cell receptor and cytokine signaling but a pronounced increase in circulating plasma B-cell activating factor (BAFF).
View Article and Find Full Text PDFArticle Synopsis
- Melatonin is studied for its potential role in managing multiple sclerosis (MS) by acting as an antioxidant and modulating the immune system, but its effects on MS patients are still not well understood.
- The objective of the study was to assess whether melatonin supplementation leads to higher levels of melatonin in the body and if it positively affects patient-reported outcomes.
- The study involved 30 individuals with relapsing forms of MS, showing that a higher dose (5 mg) resulted in increased melatonin levels compared to a lower dose (3 mg), but there were no significant improvements in fatigue or quality of life measures over 12 months.
Ocrelizumab is an effective medication for multiple sclerosis. However, infusion-related reactions (IRRs) are a concern for patients and may lead to discontinuation of ocrelizumab. To minimize IRRs, pre-medications are administered.
View Article and Find Full Text PDFIntroduction: Natalizumab is associated with a risk of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients infected with John Cunningham virus (JCV). Ocrelizumab has demonstrated efficacy to treat MS; however, its safety in patients previously treated with natalizumab is unclear.
Objective: To evaluate the safety and efficacy of ocrelizumab in patients with relapsing MS (RMS) previously treated with natalizumab.
Article Synopsis
- Natalizumab (NTZ) is effective for treating relapsing multiple sclerosis (RMS) but poses a risk of progressive multifocal leukoencephalopathy (PML) for patients with antibodies to the John Cunningham virus (JCV).
- The study evaluated the safety and effectiveness of quickly transitioning RMS patients from NTZ to teriflunomide (TFM), monitoring relapse-free status over 24 months.
- Results showed that 77% of patients were relapse-free at 24 months, with no incidence of PML, indicating that the transition was both efficacious and safe for at-risk patients.
Background: Natalizumab is an effective treatment for relapsing multiple sclerosis. Return of disease activity upon natalizumab discontinuance creates the need for follow-up therapeutic strategies.
Objective: To assess the efficacy of teriflunomide following natalizumab discontinuance in relapsing multiple sclerosis patients.